Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21935695 | 0.86 | PORCN (0.46) | TP53TRPA1RXFP1SMN1; SMN2 | |
| SCHEMBL19590905 | 0.86 | TRPA1 (0.41) | MEN1KMT2AGAATSHRMAPT | |
| SCHEMBL19590909 | 0.85 | KMT2A (0.47) | MEN1KMT2AGAATSHRMAPT | |
| SCHEMBL20030198 | 0.85 | TRPA1 (0.56) | MEN1KMT2ATSHRTRPA1ALDH1A1 | |
| SCHEMBL19590966 | 0.84 | ALDH1A1 (0.51) | KMT2AGAAMAPTTP53THRB | |
| SCHEMBL19626687 | 0.83 | SMN1; SMN2 (0.42) | MEN1KMT2AMAPTTHRBALDH1A1 | |
| SCHEMBL22105261 | 0.82 | PSEN1 (0.41) | MEN1KMT2AGAAMAPTTHRB | |
| SCHEMBL22105263 | 0.82 | PORCN (0.40) | MEN1KMT2AMAPTTP53TRPA1 | |
| SCHEMBL19997382 | 0.82 | PORCN (0.40) | MEN1KMT2AGAAMAPTTP53 | |
| SCHEMBL19590943 | 0.82 | GAA (0.45) | GAAALDH1A1L3MBTL1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351567-B2 | Methods and compositions for treating pain | ELI LILLY AND COMPANY (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351567-B2 | Methods and compositions for treating pain | ACHE, COL2A1, MMP8 | MEN1 4652/4885KMT2A 3581/4885GAA 876/4885 |
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | MEN1 4652/4885KMT2A 3581/4885GAA 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.